Mesothelin versus Ca125 in Screening the Ovarian Malignancy

Objective: To determine the sensitivity and specificity of mesothelin compared with Ca-125 as a tumor marker in predicting ovarian malignancy. Method: The cross sectional study design with diagnostic tests was conducted in 30 samples of patients undergoing elective laparotomy due to ovarian tumor. We compared the sensitivity and specificity between mesothelin and Ca-125, then the data were analyzed using SPSS software version 22.0. Result: According to the ROC curve analysis, optimal sensitivity and specificity value of mesothelin was 63.2% and 54.5% at a cut-off point of 0.45 pg/ml; or 42.1% and 72.7% at a cut-off point of 0.55 pg/ml. While the value of both optimal sensitivity and specificity of Ca-125 was 73.7% and 63.6% at a cut-off point of 46.63 U/ml. Conclusion: Mesothelin and Ca-125 are not different significantly for the AUC value of 50%. Due to higher sensitivity and specificity of Ca-125 than mesothelin, Ca-125 is still used as tumor marker for screening the ovarian malignancy. [Indones J Obstet Gynecol 2016; 4-2: 107-110] Keywords: Ca-125, mesothelin, ovarian malignanc

UJI TOKSISITAS SOFTCORAL Lobophytum Sp. TERHADAP UDANG Artemia salina, L MENGGUNAKAN METODE BRINE SHRIMP LETHALITY

Marine biota resources as a potential asset that can be used into various products including pharmaceutical products because they were a natural ingredient that very rich in biologically active compounds with a unique structure. Softcoral Lobophytum is one of the marine biota that has the secondary metabolites which can be useful in pharmacology field. The purpose of this study is to test the toxicity of the soft coral extract of Lobophytum sp as an anti-cancer biopotential. This research is using the Brine Shrime Lethality Test (BSLT) method, with laboratory experiments. Solfcoral samples were taken from Bunaken Island that using purposive sampling method. The test concentrations using 10, 100, 500 and 1000 ppm. The analysis toxicity using probit analysis for minitab program. The results showed that the increasing of concentration was  followed by the increasing of the mortality number of the animal testing. The results of probit analysis obtained an LC50 value of 9.98 ppm. These results indicate that the bioactive substance of softcoral Lobophytum sp has the potential as an anti-cancer compound. Keywords: Soft coral, Lobophytum sp, anti cancer, Artemia salina   ABSTRAK Sumber daya biota laut merupakan aset potensial yang dapat digunakan menjadi aneka produk termasuk di antaranya produk farmasi karena merupakan bahan alam yang sangat kaya senyawa aktif biologi dengan struktur yang unik. Softcoral Lobophytum salah satu biota laut yang memiliki metabloit sekunder yang dapat bermanfaat dalam bidang farmakologi. Tujuan dari penelitian ini bertujuan untuk menguji toksisitas ekstrak karang lunak Lobophytun sp sebegai biopotensi antikanker. Metode penelitiaan digunakan yaitu metode Brine Shrime Lethality  Tes (BSLT), dengan percobaan laboratorium. Sampel solfcoral diambil dari pulau Bunaken, pengambilan sampel menggunakan metode purposive sampling. Konsentrasi uji menggunakan 10, 100, 500 dan 1000 ppm. Analisis Toksisitas menggunakan analisis probit dengan  menggunakan program minitab. Hasil yang diperoleh menunjukan setiap bahwa setiap kenaikan konsentrasi diikuti dengan kenaikan jumlah mortalitas hewan uji. Hasil analisis probit diperoleh nilai LC50 9.98 mg/l. Hasil ini menunjukan bahwa susbtans bioaktif darri softcoral Lobophytum sp berpotensi sebagai senyawa antikanker. Kata kunci. Karang lunak, Lobophytum sp, anti kanker, Artemia salin

Stem cell culture conditions and stability: a joint workshop of the PluriMes Consortium and Pluripotent Stem Cell Platform

Human stem cells have the potential to transform medicine. However, hurdles remain to ensure that manufacturing processes produce safe and effective products. A thorough understanding of the biological processes occurring during manufacture of what can be very complex products, is fundamental to assuring these qualities and thus, their acceptability to regulators and clinicians. Leaders in both human pluripotent and somatic stem cells, were brought together with experts in clinical translation, bio-manufacturing and regulation, to discuss key issues in assuring appropriate manufacturing conditions for delivery of effective and safe products from these cell types. This report summarizes the key issues discussed and records consensus reached by delegates and emphasizes the need for accurate language and nomenclature in the scientific discourse around stem cells